Intravitreal dexamethasone implant for the treatment of idiopathic macular telangiectasia

Poster Details

First Author: V.Vinals Bosch SPAIN

Co Author(s):    K. Mousavi   J. Casado Martin   S. Moreno Ferrer   E. Pedemonte Sarrias                    

Abstract Details


To evaluate the efficacy of intravitreal dexamethasone implant (IDI) for the treatment of idiopathic macular telangiectasia (IMT).


Hospital Universitari Mutua Terrassa (Terrassa, Barcelona, Spain).


Retrospective case series report of six eyes (six patients) with macular edema secondary to IMT treated with IDI. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded. All patients underwent complete ophthalmic examination, spectral domain optical coherence tomography and fluorescein angiography.


The median CMT at baseline was 345 µm (306-514 µm) and diminished to 280 µm (257-313 µm) after the first injection (42 days after in average). The median BCVA at baseline was LogMAR 0.40 (0.2-0.8) and after the first injection was LogMAR 0.40 (0.2-0.7). The median follow-up period and the median number of injections received were 8 months and 1.5 injections per patient respectively. The median CMT at the last control was 301 µm (264-442 µm) and the median BCVA was LogMAR 0.40 (0.1-0.8).


Intravitreal dexamethasone implant might be an effective treatment for macular edema due to idiopathic macular telangiectasia. The BCVA maintains or improves after the first injection of IDI on these patients; even BCVA tends to diminish during the follow-up. IDI has greater impact on controlling CMT than on improving BCVA.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy